Background Basal cell carcinomas (BCCs) are common malignant skin tumors. Despite
Introduction
Basal cell carcinoma of the skin (BCC), a common human carcinoma, tends to be locally invasive and metastasizes only rarely. 1 Despite the low metastasizing ability, these lesions show significant invasion capacity if neglected. 2 This unusual predisposition makes BCC an interesting biological model for invasion and metastasis. Metastasis is a complex biological process and is controlled by various mechanisms. One important mechanism is provided by metastasis suppressor proteins (MSPs). MSPs inhibit or suppress metastasis without any effect on cell proliferation and affect different steps of the complex metastasizing process. To date, more than 30 MSPs have been identified. 3 In this study, we investigated the expression patterns of seven well-defined important MSPs, including NM23-H1, NDRG1, E-cadherin, RHOGDI2, CD82/KAI1, MKK4, and AKAP12 in BCCs.
NM23-H1 is the first described MSP and is downregulated in several metastatic cell lines and in a group of human carcinomas. 4 NM23-H1 gene encodes a nucleoside diphosphate kinase A. Although the metastasis suppressor mechanism of NM23-H1 is not clear, its interaction with kinase suppressors of RAS and, as a result, alteration of the MAPK signaling pathway is a probable mechanism. 3 It has also recently been suggested that it suppresses metastasis by inhibiting the expression of EDG2 (lysophosphatidic acid receptor).
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NDRG1 (N-myc downstream regulated 1) is a member of the NDRG family of proteins and has been shown to reduce metastasis in colon, breast, and prostate neoplasms. 6 Although the metastasis suppressor mechanism of NDRG1 is not clear, the interaction with the cell-cell adhesion molecules b-catenin and E-cadherin might be a possible mechanism. 7, 8 E-cadherin is a well-known cell-cell adhesion protein, and loss of its expression plays important roles in tumor invasion and metastasis. 9, 10 It also functions as a negative regulator of the canonical WNT signaling pathway. E-cadherin has been extensively studied in human tumors, including BCCs. 11, 12 RHOGDIs (Rho GDP-dissociation inhibitors) make up a small group of proteins that negatively control RhoGTPases, which play important roles in cancer and metastasis. 13 RHOGDI2 acts as an MSP in bladder tumors and probably in other types of epithelial tumors. 14 However, RHOGDI2 may have cancer or tissue-specific functions in tumor suppression, while it might promote cancer invasiveness in a minority of human cancers. 14, 15 The CD82/KAI1 protein, also called TSPAN27, is a member of the tetra-spantin family, which has important roles in adhesion, motility, and tumor progression. 16, 17 It was initially demonstrated as an MSP in prostate carcinoma. 18 The prognostic importance of this protein was then demonstrated in other human cancer types. 17, 19, 20 Mitogen-activated protein kinase kinase 4 (MKK4) is a component of MAP kinase in stress-activated protein kinase signaling. 21, 22 It was identified as an MSP in prostate and ovarian cancer. 23, 24 Although the tumor or metastasis suppressor function of MKK4 is generally accepted, there are also some clues that it has pro-oncogenic roles.
22
AKAP12, also called SSeCKS/Gravin, is a scaffold protein and functions as a binding partner of protein kinase C and A, calmodulin, F-actin, cyclins, Src, and phospholipids. 25 Significant clinical and experimental evidence has shown that AKAP12 is an important tumor and metastasis suppressor. 25 AKAP12 expression is downregulated in various solid human cancers and some leukemias. 25, 26 The significance of MSPs in BCC is not well known due to the limited number of studies (Table 1) . Our aim was to demonstrate the distribution and expression of the seven important MSPs in BCC. We also tried to determine the relationship between protein expression levels, p53 status, and well-known clinicopathological parameters.
Materials and methods

Study group
A total of 96 BCCs from 92 patients (47 male/45 female) were included in this study. All patients were Caucasian, and the mean age was 66.3 AE 13.4 years. All lesions were excised from the head and neck area except for five lesions from the trunk. Normal epidermis samples adjacent to the BCCs (NE-BCC) and 10 nonlesional, histopathologically confirmed normal skin tissues (N) were also studied. As there is no easy way to subclassify BCCs because of their wide and heterogeneous morphological spectrum, we used the criteria summarized by Carr et al. for classifying our group. 27 Two major tumor groups were created and immunohistochemically scored to establish the differential expression patterns and contribution of the proteins:
1 Morphologically non-aggressive BCC types, including nodular, adenoid, superficial, and mixed carcinomas with less than 50% infiltrative pattern (n = 68).
Morphologically aggressive BCC types, including infiltrative
BCCs with/without desmoplasia and mixed carcinomas with more than 50% infiltrative pattern (n = 28).
Clinicopathological features
The conventional clinicopathological parameters, including maximum diameter of the tumor, invasion depth, perineural invasion, anatomical invasion (Clark's) level, and local recurrences, were investigated. Tumor-associated inflammation was graded as previously described by Kaur et al.
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Immunohistochemistry Table 2 .
Immunohistochemical analyses
The immunohistochemistry results were analyzed semiquantitatively by using an immunohistochemical histological score (HSCORE) that included both the intensity and proportional distribution of specific staining. Based on a specific method described by McCarty et al., the HSCORE has been formulated as HS = ∑ (P i 9 i/100), where P i indicates the percentage of stained cells (0-100%) at each intensity and i shows the intensity of staining and ranges from no staining (0 points) to strong staining (3 points). 29 The calculated HSCOREs were between 0 (no staining) and 300
(strong-diffuse staining) points. All calculations were performed with the Microsoft Office Excel â program using a simple macro. After evaluating the whole slide for specific staining, a minimum of five to seven randomly selected areas at medium power magnification (920) in normal and neoplastic tissues were analyzed for HSCORE. Nuclear ( nuc ) and cytoplasmic ( cyt ) expressions were evaluated separately for NM23-H1, MKK4, RHOGDI2, and NDRG1. Only membranocytoplasmic staining of E-cadherin, AKAP12, and CD82, and nuclear staining of p53 were accepted as positive.
Statistical analysis
Statistical analyses were performed using the PASW 
Results
Immunohistochemical staining
In normal epidermis (N), all of the proteins were expressed at various intensities. NDRG1, E-cadherin, RHOGDI2, and cytoplasmic NM23-H1 positivity was International Journal of Dermatology 2014 ª 2014 The International Society of Dermatology strong and easily detectable. However, nuclear NM23-H1 was only seen in the basal layers of the epidermis. AKAP12, CD82/KAI, and cytoplasmic MKK4 were stained at medium intensities. Nuclear staining of MKK4 was very weak and not easily detectable. NE-BCC showed more heterogeneous positivity with all antibodies when compared to the normal epidermis. In BCCs, both cytoplasmic (NDRG1 cyt ) and nuclear NDRG1 (NDRG1 nuc ) positivity were homogeneous (Fig.  2c, d ). NDRG1 cyt was seen in all BCCs. However, only 74 of 96 (77%) BCCs showed nuclear positivity. Similarly, NM23-H1 cytoplasmic expression (NM23-H1cyt) was also strong and diffused, except in two BCCs (97.9%) (Fig. 2a, b) . Nuclear expression of NM23-H1 was weaker and expressed in 73 of 96 (76%) cases. ECadherin antibody was represented by both membranous and cytoplasmic positivity except in seven BCCs (92.7%) (Fig. 2e, f) . Nuclear staining was seen very rarely and usually in strongly stained areas. CD82/KAI and AKAP12 positivity was significantly reduced and only seen in focal areas of the BCCs in 14 (15.1%) and 21 of 96 (21.8%) cases, respectively (Fig. 3c-f ). MKK4 immunostaining of neoplastic tissues was weak/medium cytoplasmic positive in 73 (76%) and weak nuclear positive in only 35 (36.4%) cases (Fig. 3a,b) . The nuclear expression was more evident in normal tissues. Although RHOGDI2 staining showed cytoplasmic positivity (RHOGDI2 cyt ) in 89 of 96 (92.7%) cases, the intensity was significantly reduced (Fig. 2g,h ). Nuclear expression (RHOGDI2 nuc ) was very weak and heterogeneously in 59 (61.4%) of 96 BCCs.
HSCORES
The HCORES of the groups are demonstrated in the boxplot graph (Fig. 1) .
Statistical results
As the tumor microenvironment changes are part of carcinogenesis, we evaluated the difference between the NE-BCC and normal non-lesional (N) skin. Although there was no statistical difference for RHOGDI2 cyt , NM23-H1 cyt/nuc , CD82, and MKK4 cyt/nuc scores between the two groups, the other markers showed a significant reduction in NE-BCC (P ≤ 0.05).
When normal epidermis was compared to BCCs, all of the scores except for NM23 cyt/nuc were significantly lower in the tumor groups (P ≤ 0.01). Similarly, when NE-BCC was compared to BCCs, all of the markers except for NM23-H1 cyt and NDRG1 cyt indicated significantly reduced scores (P ≤ 0.01) in the BCC group. Furthermore, NM23-H1 nuc scores were higher in BCCs than in NE-BCC. Table 3 qRT-PCR primer sequences used in this study Morphologically aggressive BCCs expressed significantly higher NDRG1 cyt scores (P = 0.001) and lower CD82/KAI1 scores (P = 0.048).
BCCs with perineural invasion showed lower nuclear NM23-H1 levels (P = 0.01). Recurrent BCCs expressed higher RHOGDI2 nuc levels (P = 0.01) when compared to the non-recurrence group.
Correlation analysis
In the BCC group, there were significant correlations (P = 0.01 level) between several markers as follows: NM23-H1 nuc -NM23-H1 cyt (r = 0.442); AKAP12-RHOGDI2 cyt (r = 0.333); AKAP12-NDRG1 cyt (r = 0.280); E-cadherin-RHOGDI2 cyt (r = 0.303); E-cadherin-NDRG1 cyt (r = 0.413); RHOGDI2 nuc -RHOGDI2 cyt (r = 0.405); RHO-GDI2 nuc -MKK4cyt (r = À0.294); NDRG1 nuc -NDRG1 cyt (r = 0.356); and MKK4 nuc -MKK4 cyt (r = 0.365). There were also significant negative correlations between AKAP12 and inflammation (r = À0.275; P = 0.007).
A randomly selected subgroup of 44 BCCs from the main group was stained with p53 primary antibody to establish the correlation between MSPs and p53. We detected only a negative correlation with RHOGDI2 cyt (r = À0.316; P = 0. 037).
Relative expression software tool (REST) analysis of quantitative real-time polymerase chain reaction data
BCCs were compared to both the normal non-lesional skin tissue and the skin adjacent to neoplasia groups. We found significant upregulation of NM23 (1.4-fold, P = 0.032) and downregulation of AKAP12 (À1.2-fold; P = 0.006) when BCC was compared to normal skin. NDRG1 showed statistically significantly higher levels (2.2-fold, P = 0.001) in BCC when compared to the skin adjacent to the neoplasia, similar to the immunohistochemical results.
Discussion
Invasion and metastasis are the most important hallmarks of cancer and well-known clinical signs of a poor prognosis. 31, 32 BCCs display all the hallmarks of cancer, including invasion, with the exception of metastasis. To date, the question of why BCCs metastasize only rarely has not been adequately answered. A possible but unsupported explanation for this question is the strict stromal dependence of BCC. 33 In this study, we examined the contribution of the MSPs in the non-metastasizing feature of BCCs and focused on seven well-known proteins. We detected that NM23-H1 HSCOREs were protected in BCCs, and mRNA level of NM23-H1 was higher in BCCs than in normal skin. Similarly, Ro and Jeong and Kanitakis et al. focused on the NM23-H1 protein in skin lesions and both found medium/strong NM23-H1 positivity in all BCCs. 34, 35 In spite of the significant expression of NM23-H1 in BCCs, its importance is not well known. However, it has been shown that NM23-H1 expression is inversely related to the metastasis status in other human carcinomas. 36 The significant NM23-H1 expression in
BCCs probably contributes to their non-metastasizing feature.
One of the important results of this study is the demonstration of significant cytoplasmic NDRG1 expression in BCC, which is also supported with the qRT-PCR study. Although NDRG1 expression has not been studied in BCC previously, Cangul demonstrated that human carcinomas expressed high levels of NDRG1 compared to their normal counterpart, 37 and the prognostic importance of NDRG1 expression has been pointed out in various human tumors. [38] [39] [40] [41] We also found a significant correlation between NDRG1 cyt (P = 0.001) and E-cadherin in BCCs, and this relationship was reported in the literature in colon and prostate carcinomas. 8, 42, 43 Our data clearly support an E-cadherin/NDRG1 pathway in human carcinomas. Besides NM23-H1 and NDRG1, E-cadherin expression was generally preserved in 92.7% of BCCs with relatively higher HSCORES, and qRT-PCR studies also showed no statistically significant difference from normal skin tissue. The data from the literature and our study show that E-cadherin positivity is expected in BCC, even if at reduced levels compared to the normal epidermis (Table 1) .
CD82/KAI1 and AKAP12 expressions were significantly reduced or completely lost in all morphological subtypes of BCCs. We also detected downregulation of AKAP12 mRNA in BCC. Similar to our results, the downregulation of CD82/KAI1 expression in BCCs was demonstrated before. 44 Yet, the expression pattern of AKAP12 is still not known in BCCs, a recent article pointed out that the methylation frequencies of the AKAP12 gene were significantly higher in skin carcinomas than normal skin tissue. 45 CD82/KAI1 and AKAP12 probably have no contribution to the non-metastatic features of BCCs. However, we believe that these proteins are interesting negative markers for BCCs, and further studies might show their role in the differential diagnosis.
One of the goals of the study was to show the correlation between the MSPs, and important clinicopathological parameters and p53 in BCCs. We found AKAP12 inversely correlated with inflammation, together with an inverse relationship between NM23-H1 nuc and perineural invasion. Besides these expected correlations, we found that recurrences were correlated only with RHOGDI2 nuc . This result may be explained by the dual and unpredicted role of RHOGDI2 in carcinomas as proposed by Griner and Theodorescu. 14 We found only an inverse correlation between RHOGDI2 cyt and p53. Although the relationship between p53 and RHOGDI2 has not been demonstrated previously, interaction between p53 and CD82/KAI1, another MSP, has been reported. [46] [47] [48] However, other studies have been querying this correlation, similar to our results. [49] [50] [51] [52] One of the major questions in this study is the contribution of MSPs to the aggressive phenotype of BCCs. We detected upregulation of NDRG1 levels in the aggressive phenotype (P = 0.001). Similarly, CD82/KAI levels (P = 0.048) were downregulated. In the literature, E-cadherin levels have been shown to be downregulated in aggressive BCCs, 11, 53 but this has not been supported by other studies (Table 1) . These results may show a slightly different profile of MSPs in aggressive carcinomas than non-aggressive BCCs.
In conclusion, we have demonstrated differential expression patterns for the seven MSPs in BCCs. AKAP12 and CD82/KAI1 levels were significantly reduced in BCCs. However, NM23-H1, NDRG1, and E-cadherin levels were minimally reduced, and they were generally expressed in this neoplasm group. The other markers, MKK4 and RHOGDI2, were also reduced but not lost in BCCs. Although this is a very simplified approach, preserved levels of NM23-H1, E-cadherin, and NDRG1 may contribute to the non-metastatic features of BCCs. One of our important findings is there are plenty of significant correlations among the MSPs. Data from this study might reveal possible pathways between MSPs, when combined with the current knowledge on pathways. This relationship between these MSPs warrants further biological and experimental pathway research.
